Breaking Finance News

Arbutus Biopharma (NASDAQ:ABUS) stock price target increased to $3.00, issued a research note today by Chardan Capital

Yesterday Arbutus Biopharma (NASDAQ:ABUS) traded -2.97% lower at $2.94. The company’s 50-day moving average is $3.66 and its 200-day moving average is $4.02. The last closing price is down -26.82% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 165,521 shares of the stock traded hands, up from an average trading volume of 122,688

In a report released on 10/14/2016 Chardan Capital increased the stock price target of Arbutus Biopharma (NASDAQ:ABUS) to $3.00 indicating a possible upside of 0.02%.

Previously on Wednesday October 05, 2016, Zacks Investment Research reported on Arbutus Biopharma (NASDAQ:ABUS) increased the target price from $0.00 to $4.00. At the time, this indicated a possible upside of 0.09%.

See Chart Below

Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma has a 52 week low of $2.72 and a 52 week high of $6.74 The company’s market cap is currently $0.

In addition to Chardan Capital reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is $13.80 with 2 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.